PROCARDIA Drug Patent Profile

When do Procardia patents expire, and when can generic versions of Procardia launch?

Procardia is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in PROCARDIA is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Procardia

A generic version of PROCARDIA was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Summary for PROCARDIA

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for PROCARDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-002	Sep 6, 1989	AB2	RX	Yes	No
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986		DISCN	Yes	No

International Patents for PROCARDIA

See the table below for patents covering PROCARDIA around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	7205808
German Democratic Republic	99729
Singapore	34877

Investment Scenario and Fundamentals Analysis for PROCARDIA (Nifedipine Extended-Release)

Last updated: February 24, 2026

What Are the Core Market Dynamics?

Procaria (Nifedipine ER, marketed as PROCARDIA) is a calcium channel blocker used primarily to treat hypertension and angina. The drug’s global market is driven by increasing prevalence of cardiovascular diseases, aging populations, and expanding healthcare access in emerging markets.

Key Market Drivers

• Rising Hypertension and Cardiovascular Disease Prevalence: According to the WHO, over 1.2 billion people globally have hypertension, a prime target for PROCARDIA.
• Aging Populations: Geriatric populations exhibit higher rates of hypertension requiring long-term management.
• Expand Access and Adoption: Increased use in outpatient settings and adherence to guidelines favor extended-release formulations.

Market Size & Forecast

Year	Global Hypertension Market (USD billions)	CAGR	Relevant Segment (Nifedipine ER) Share
2022	45.2	6.3%	22%
2027	66.4	8.1%	24%

The Nifedipine ER segment is projected to grow faster than the overall hypertension market due to preference for once-daily dosing and improved side effect profile.

How Does Competitive Positioning Look?

Major Competitors

• Adalat CC (Bayer): Established brand with high prescriber loyalty.
• Nifedipine-XL (Meda/Meda-AB): Generic formulations dominate price-sensitive markets.
• Others: Combination therapies and newer agents in development.

Market Share

Company	Estimated Global Market Share (2022)	Key Strengths
Bayer	40%	Brand recognition, broad distribution
Generic Manufacturers	35%	Competitive pricing, wide availability
Patent-Lapsed Drugs	25%	Price advantage, growing usage

Market penetration correlates with pricing strategies, with generics capturing larger portions as patent exclusivity expires.

Patent and Regulatory Landscape

Patent Status

• The original Bayer patent for PROCARDIA expired in major markets after 2012, leading to a surge in generics.
• Patent extensions are rare due to expiration, limiting barriers for new entrants but increasing price competition.

Regulatory Pathways

• Available in major jurisdictions (FDA, EMA, etc.).
• Regulatory approval relies on bioequivalence for generic entries.
• Significant approvals include indications for hypertension and angina.

Reimbursement & Pricing Policies

• Insurance coverage varies by country.
• In the U.S., outpatient prescriptions typically have favorable reimbursement for branded and generic Nifedipine ER.
• Price erosion in generics reduces margins, pressure on branded formulations.

R&D and Pipeline Considerations

• Limited ongoing R&D for PROCARDIA-specific formulations.
• Focus on combination therapies and new delivery devices for related calcium channel blockers.
• Potential innovation venues include extended-release technology and bioavailability improvements.

Investment Risks

• Rapid generics proliferation diminishes profitability.
• Market saturation in developed economies.
• Regulatory and reimbursement uncertainties in emerging markets.
• Competition from new antihypertensive agents, including ARBs and ACE inhibitors.

Financial Fundamentals

Parameter	Typical Values / Trends
Gross Margin	60–70% for branded, 40–50% for generics
Market Penetration	Stabilizes post-patent expiry, declines for brand dominance
R&D Spend	Low, mostly focused on optimizing existing formulations
Operating Expenses	Includes marketing commercialization costs

Conclusion

While PROCARDIA remains a mainstay in hypertension therapy, current dynamics favor generic competition and price erosion. Its investment appeal depends on market share retention, geographic expansion, and potential in emerging markets. The lack of innovative R&D limits upside potential but offers stable cash flows in mature markets.

---

Key Takeaways

• The global hypertension market is growing rapidly, but PROCARDIA’s brand dominance has waned due to patent expiry.
• Generics hold a combined 35% market share, with pricing pressures affecting revenues.
• Regulatory and reimbursement environments vary, influencing market access.
• Limited pipeline activity reduces long-term innovation upside but maintains existing revenue streams.
• Investment risks include market saturation, intense competition, and evolving treatment guidelines.

---

FAQs

1. What is the primary use of PROCARDIA?
It treats hypertension and angina by dilating coronary arteries and reducing blood pressure.

2. How does patent expiration impact PROCARDIA’s market share?
Patent expiry in 2012 led to increased generic competition and reduced brand pricing power.

3. What are the main factors driving the hypertension drug market?
Growing global prevalence of hypertension, aging populations, and increased healthcare access.

4. Are there ongoing R&D efforts for PROCARDIA?
R&D is minimal; most activity focuses on formulation improvements or combination therapies.

5. What risks should investors watch for in PROCARDIA?
Market saturation, commoditization from generics, regulatory changes, and competition from newer drugs.

---

References

[1] World Health Organization. (2022). Hypertension fact sheet.
[2] IMS Health. (2022). Global hypertension market report.
[3] U.S. Food and Drug Administration. (2021). Bioequivalence guidelines for generic drugs.
[4] Bayer AG. (2022). Annual report.
[5] MarketWatch. (2022). Generic drug market dynamics.